Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-10T10:14:12.319Z Has data issue: false hasContentIssue false

Trends in beta-hemolytic Streptococcus infections within Veterans’ Affairs medical centers from 2009 to 2018

Published online by Cambridge University Press:  06 September 2021

GiGi Yam
Affiliation:
Department of Pharmacy, Western NY VA Healthcare System, Buffalo, New York
Bethany A. Wattengel
Affiliation:
Department of Pharmacy, Western NY VA Healthcare System, Buffalo, New York
Michael T. Carter
Affiliation:
Department of Pharmacy, Western NY VA Healthcare System, Buffalo, New York
John A. Sellick*
Affiliation:
Department of Infectious Diseases, Western NY VA Healthcare System, Buffalo, New York University at Buffalo, Jacobs School of Medicine, Buffalo, New York
Alan J. Lesse
Affiliation:
Department of Infectious Diseases, Western NY VA Healthcare System, Buffalo, New York University at Buffalo, Jacobs School of Medicine, Buffalo, New York
Kari A. Mergenhagen*
Affiliation:
Department of Pharmacy, Western NY VA Healthcare System, Buffalo, New York
*
Author for correspondence: Kari A. Mergenhagen, E-mail: Kari.Mergenhagen@va.gov. Or John A. Sellick, E-mail: John.Sellick@va.gov
Author for correspondence: Kari A. Mergenhagen, E-mail: Kari.Mergenhagen@va.gov. Or John A. Sellick, E-mail: John.Sellick@va.gov

Abstract

Objective:

The purpose of this study was to describe the recent trends of invasive and noninvasive β-hemolytic Streptococcus cultures in the Veterans’ Affairs (VA) cohort from 2009 to 2018.

Design:

Retrospective cohort study from January 1, 2009, to January 1, 2019.

Setting:

Veterans’ Affairs medical centers.

Patients or participants:

All patients aged 18 years and older with cultures positive for β-hemolytic Streptococcus at a VA facility were included in the study.

Intervention(s):

Data were retrieved from the VA Corporate Data Warehouse using structure query language through the SQL Server Management Studio software.

Results:

Between 2009 and 2018, there were 40,625 patients with cultures with β-hemolytic Streptococcus. The median age was 64 years (interquartile range [IQR], 55–71) and the median Charlson comorbidity index was 4 (IQR, 2–7). Distributions for each type of β-hemolytic Streptococcus based on site of culture are provided. The 30-day all-cause mortality rate from all invasive β-hemolytic Streptococcus cases was 2.3%, and the 90-day all-cause mortality rate was 4.4%. The 30- and 90-day all-cause mortality rates for Streptococcus cases were higher for group A (3.9% and 6.1% respectively) and for groups C and G combined (3.2% and 6.1%, respectively) than for group B (2.0% and 4.0%, respectively).

Conclusions:

Trends of cultures for invasive and noninvasive β-hemolytic Streptococcus suggest an association with disease and mortality. The burden associated with β-hemolytic Streptococcus infections should not be underestimated.

Type
Original Article
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Active bacterial core surveillance report, Emerging Infections Program Network, group A Streptococcus, 1997–2017, 1998–2018. Centers for Disease Control and Prevention website. https://www.cdc.gov/abcs/reports-findings/surv-reports.html. Accessed January 14, 2021.Google Scholar
Active bacterial core surveillance report, Emerging Infections Program Network, group B Streptococcus, 1997–2017, 1998–2018. Centers for Disease Control and Prevention website. https://www.cdc.gov/abcs/reports-findings/surv-reports.html. Accessed January 14, 2021.Google Scholar
Jump, RLP, Wilson, BM, Baechle, D, et al. Risk factors and mortality rates associated with invasive group B Streptococcus infections among patients in the US Veterans’ Health Administration. JAMA Netw Open 2019;2(12):e1918324-e.10.1001/jamanetworkopen.2019.18324CrossRefGoogle Scholar
Skoff, TH, Farley, MM, Petit, S, et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990–2007. Clin Infect Dis 2009;49:8592.10.1086/599369CrossRefGoogle Scholar
Francois Watkins, LK, McGee, L, Schrag, SJ, et al. Epidemiology of invasive group B streptococcal infections among nonpregnant adults in the United States, 2008–2016. JAMA Intern Med 2019;179:479488.10.1001/jamainternmed.2018.7269CrossRefGoogle ScholarPubMed
Nelson, GE, Pondo, T, Toews, K-A, et al. Epidemiology of invasive group A streptococcal infections in the United States, 2005–2012. Clin Infect Dis 2016;63:478486.10.1093/cid/ciw248CrossRefGoogle ScholarPubMed
O’Loughlin, RE, Roberson, A, Cieslak, PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000–2004. Clin Infect Dis 2007;45:853862.10.1086/521264CrossRefGoogle ScholarPubMed
Schwartz, IS, Keynan, Y, Gilmour, MW, Dufault, B, Lagace-Wiens, P. Changing trends in beta-hemolytic streptococcal bacteremia in Manitoba, Canada: 2007–2012. Int J Infect Dis 2014;28:211213.10.1016/j.ijid.2014.03.1376CrossRefGoogle ScholarPubMed
Oppegaard, O, Mylvaganam, H, Kittang, BR. Beta-haemolytic group A, C and G streptococcal infections in western Norway: a 15-year retrospective survey. Clin Microbiol Infect 2015;21:171178.10.1016/j.cmi.2014.08.019CrossRefGoogle Scholar
Oppegaard, O, Mylvaganam, H, Skrede, S, Lindemann, PC, Kittang, BR. Emergence of a Streptococcus dysgalactiae subspecies equisimilis stG62647-lineage associated with severe clinical manifestations. Sci Rep 2017;7:7589.10.1038/s41598-017-08162-zCrossRefGoogle ScholarPubMed
Lambertsen, LM, Ingels, H, Schonheyder, HC, Hoffmann, S. Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011. Clin Microbiol Infect 2014;20:O216O223.10.1111/1469-0691.12378CrossRefGoogle ScholarPubMed
Verani, JR, McGee, L, Schrag, SJ. Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. MMWR Recommend Rep 2010;59(Rr-10):136.Google Scholar
Oppegaard, O, Skrede, S, Mylvaganam, H, Kittang, BR. Temporal trends of beta-haemolytic streptococcal osteoarticular infections in western Norway. BMC Infect Dis 2016;16:535.10.1186/s12879-016-1874-7CrossRefGoogle ScholarPubMed
Ekelund, K, Skinhoj, P, Madsen, J, Konradsen, HB. Invasive group A, B, C, and G streptococcal infections in Denmark 1999–2002: epidemiological and clinical aspects. Clin Microbiol Infect 2005;11:569576.10.1111/j.1469-0691.2005.01169.xCrossRefGoogle Scholar
Rantala, S, Vuopio-Varkila, J, Vuento, R, Huhtala, H, Syrjanen, J. Predictors of mortality in beta-hemolytic streptococcal bacteremia: a population-based study. J Infect 2009;58:266272.10.1016/j.jinf.2009.01.015CrossRefGoogle ScholarPubMed
Broyles, LN, Van Beneden, C, Beall, B, et al. Population-based study of invasive disease due to β-hemolytic streptococci of groups other than A and B. Clin Infect Dis 2009;48:706712.10.1086/597035CrossRefGoogle ScholarPubMed
Bencardino, D, Di Luca, MC, Petrelli, D, Prenna, M, Vitali, LA. High virulence gene diversity in Streptococcus pyogenes isolated in central Italy. Peer J 2019;7:e6613.10.7717/peerj.6613CrossRefGoogle ScholarPubMed